



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Heinrich *et al.*

Application No. 10/517,905

Filed: December 10, 2004

Confirmation No. 4619

For: ACTIVATING MUTATIONS OF  
PLATELET DERIVED GROWTH  
FACTOR RECEPTOR ALPHA (PDGFRA)  
AS DIAGNOSTIC MARKERS AND  
THERAPEUTIC TARGETS

Examiner: \_\_\_\_\_

Art Unit: \_\_\_\_\_

Attorney Reference No. 899-65892-02

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Name: Debra K. SmithDate Mailed January 23, 2006

MAIL STOP MISSING PARTS  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Applicants have received the official Filing Receipt for the application referenced above, a copy of which (with requested corrections shown in red ink) is attached as Exhibit A.

The following error(s) appears on the Filing Receipt:

ITEM IN ERROR	CORRECT INFORMATION
Applicant(s) Michael C Heinrich	Applicant(s) Michael C. Heinrich
Applicant(s) Christopher C Corless	Applicant(s) Christopher <u>L.</u> Corless
Applicant(s) Jonathan A. Fletcher, Brookline, MA	Applicant(s) <u>Jonathan A. Fletcher, Brookline, MA</u>
Applicant(s) George D. Demetri, Brookline, MA	Applicant(s) <u>George D. Demetri, Brookline, MA</u>
ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTICS TARGETS	ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC_ TARGETS

Applicants have shown the corrections in bold and underline to better show the corrections to be made. Applicants request that the identified errors be corrected and that a new official Filing Receipt be issued.

Please return the enclosed postcard to confirm that the items listed above have been received, and please call the undersigned if any further information is required.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By: Debra A. Gordon  
Debra A. Gordon, Ph.D.  
Registration No. 54,128

cc: Docketing

DHSU/TMH



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/517,905	12/10/2004	1646	1500	899-65892-02	7	60	3

CONFIRMATION NO. 4619

## FILING RECEIPT



\*OC000000017551672\*

24197  
KLARQUIST SPARKMAN, LLP  
121 SW SALMON STREET  
SUITE 1600  
PORTLAND, OR 97204

PREVIOUSLY DOCKETED

Date Mailed: 12/30/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Michael C. Heinrich, Lake Oswego, OR; ✓  
Christopher C. Corless, Portland, OR;

Michael C. Heinrich

Christopher L. Corless

Jonathan A. Fletcher, Brookline, MA

George D. Demetri, Brookline, MA

## Assignment For Published Patent Application

Brigham And Women's Hospital, Boston, MA ✓  
Oregon Health & Science University, Portland, OR ✓  
Dana-Farber Cancer Institute, Boston, MA ✓

Power of Attorney: The patent practitioners associated with Customer Number 24197. ✓

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US03/18901 06/13/2003 ✓  
which claims benefit of 60/389,107 06/13/2002 ✓  
and claims benefit of 60/438,899 01/08/2003 ✓

## Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No ✓

Early Publication Request: No ✓

EXHIBIT A

**\*\* SMALL ENTITY \*\*** ✓

**Title**

Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutics targets

**Preliminary Class**

435

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

### LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted

under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/517,905	FIRST NAMED APPLICANT Michael C Heinrich	ATTY. DOCKET NO. 899-65892-02
---	---	----------------------------------

24197  
 KLARQUIST SPARKMAN, LLP  
 121 SW SALMON STREET  
 SUITE 1600  
 PORTLAND, OR 97204

INTERNATIONAL APPLICATION NO. PCT/US03/18901	
LA. FILING DATE 06/13/2003	PRIORITY DATE 06/13/2002

CONFIRMATION NO. 4619

371 ACCEPTANCE LETTER



Date Mailed: 12/30/2005

## NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>12/10/2004</u>	<u>12/10/2004</u>
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS	DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE " FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- Indication of Small Entity Status
- Copy of the International Application filed on 12/10/2004
- Preliminary Amendments filed on 12/10/2004
- Information Disclosure Statements filed on 07/01/2005
- Biochemical Sequence Diskette filed on 12/10/2004
- Oath or Declaration filed on 12/10/2004
- Biochemical Sequence Listing filed on 12/10/2004
- Small Entity Statement filed on 12/10/2004
- Request for Immediate Examination filed on 12/10/2004
- U.S. Basic National Fees filed on 12/10/2004
- Priority Documents filed on 12/10/2004

- Specification filed on 12/10/2004
- Claims filed on 12/10/2004
- Abstracts filed on 12/10/2004
- Drawings filed on 12/10/2004
- Paper nucleotide sequence listings filed on 12/10/2004
- Paper Computer Listings filed on 12/10/2004

---

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

---

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)



TMH/DX cas\_1/23/06 899-65892-02 477934.doc 614

PATENT  
Attorney Reference Number 899-65892-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Heinrich et al.

**Application No.** 10/517,905

**Filed:** December 10, 2004

**Confirmation No.** 4619

**For:** ACTIVATING MUTATIONS OF PLATELET  
DERIVED GROWTH FACTOR RECEPTOR  
ALPHA (PDGFRA) AS DIAGNOSTIC  
MARKERS AND THERAPEUTIC TARGETS

**Examiner:**

**Art Unit:**

**Attorney Reference No.** 899-65892-02

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

*Debra A. Gordon*

Date Mailed January 23, 2006

MAIL STOP MISSING PARTS  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Request for Corrected Official Filing Receipt.
- ☒ Exhibit A.
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By *Debra A. Gordon*

Debra A. Gordon, Ph.D.

Registration No. 54,128

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446  
cc: Docketing